AtaiBeckley (ATAI) Proxy filing summary

Executive summary

• Entered into a definitive agreement for acquisition by Eli Lilly, expected to close in Q3 2026 pending shareholder and regulatory approvals.

• Transaction includes Nualtis, a subsidiary with a key oral thin-film platform for depression treatment.

• Operations, compensation, and benefits remain unchanged until closing; integration planning will occur over time.

• Communication emphasizes business continuity and ongoing commitment to customers and partners.

• Forward-looking statements highlight potential benefits, risks, and uncertainties related to the merger and its impact.

Voting matters and shareholder proposals

• Merger requires approval by stockholders at a special meeting; proxy statement will be filed and mailed to eligible voters.

• Stockholders are encouraged to review proxy materials and vote on the adoption of the merger agreement.

Board of directors and corporate governance

• Directors, executive officers, and certain employees may be deemed participants in the proxy solicitation.

• Information on board and executive stock ownership and compensation is available in the 2026 Proxy Statement and recent SEC filings.